Combined trimethoprim and caspofungin treatment for severe Pneumocystis jiroveci pneumonia in a five year old boy with acute lymphoblastic leukemia

Klinische Padiatrie

Volumn 218, Issue 3, 2006, Pages 177-179

  Beltz, K ^a   Kramm, Christof M ^a,b   Laws, H J ^a   Schroten, H ^a   Wessalowski, R ^a   Gobel U ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^b NONE   (Germany)

Author keywords

Acute respiratory failure; Immunosuppression; Pneumocystis jiroveci pneumonia

Indexed keywords

CASPOFUNGIN; COTRIMOXAZOLE; GANCICLOVIR; METHOTREXATE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANAMNESIS; ARTICLE; ARTIFICIAL VENTILATION; BONE MARROW TOXICITY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DISEASE COURSE; DISEASE SEVERITY; DOSE RESPONSE; DRUG TOLERABILITY; FEVER; FLOW CYTOMETRY; HUMAN; MALE; MUCOSA INFLAMMATION; NEUTROPENIA; PNEUMOCYSTIS PNEUMONIA; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; THORAX RADIOGRAPHY; TREATMENT OUTCOME; WEAKNESS;

ANTIBIOTIC PROPHYLAXIS; ANTIFUNGAL AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CD4 LYMPHOCYTE COUNT; CHILD, PRESCHOOL; DRUG THERAPY, COMBINATION; FOLLOW-UP STUDIES; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; MALE; OPPORTUNISTIC INFECTIONS; PEPTIDES, CYCLIC; PNEUMOCYSTIS JIROVECI; PNEUMONIA, PNEUMOCYSTIS; REMISSION INDUCTION; TOMOGRAPHY, X-RAY COMPUTED; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 33744483801     PISSN: 03008630     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-933433     Document Type: Article

References (12)

1. Annaloro C, Della Volpe A, Usardi P, Lambertenghi Deliliers G. Caspofungin treatment of Pneumocystis pneumonia during conditioning for bone marrow transplantation. Eur J Clin Microbiol Infect Dis 2005; 20: 1-3
2. Eckert C, Biondi A, Seeger K et al. Prognostic value of minimal residual disease in relapsed childhood acute lymphblastic leukaemia. Lancet 2001; 358: 1239-1241
3. Ewig S, Bauer T, Schneider C et al. Clinical characteristics and outcome of Pneumocystis jiroveci pneumonia in HIV-infected and otherwise immunosuppressed patients. Eur Respir J 1995; 8: 1548-1553
4. Groll AH, Lehrnbecher T. New antifungal drugs and the pediatric cancer patient: current status of clinical development. Klin Padiatr 2005; 217: 158-168
5. Groll AH, Ritter J. Diagnosis and management of fungal infections and pneumocystis pneumonitis in pediatric cancer patients. Klin Padiatr 2005; 217 (Suppl 1): S37-S66
6. Groll AH, Walsh TJ. Caspofungin: pharmacology, safety and therapeutic potential in superficial and invasive fungal infections. Expert Opin Investig Drugs 2001; 10: 1545-1558
7. Harms DO, Janka-Schaub GE. Co-operative study group for childhood acute lymphblastic leukemia (COALL): long-term follow-up of trials 82, 85, 89 and 92. Leukemia 2000; 14: 2234-2239
8. Pagano L, Fianchi L, Mele L et al. Pneumocystis jiroveci pneumonia in patients with malignant haematological diseases: 10 years' experience of infection in GIMEMA centres. Br J Haematol 2002; 117: 379-386
9. Powles MA, Liberator P, Anderson J et al. Efficacy of MK-991 (L-743, 872), a semisynthetic pneumocandin, in murine models of Pneumocystis jiroveci. Antimicrob Agents Chemother 1998; 42: 1985-1989
10. Roblot F, Godet C, Le Moal G et al. Analysis of underlying diseases and prognosis factors associated with Pneumocystis jiroveci pneumonia in immunocompromised HIV-negative patients. Eur J Clin Microbiol Infect Dis 2002; 21: 523-531
11. Yang CH, Yang LJ, Jaing TH, Chan HL. Toxic epidermal necrolysis following combination of methotrexate and trimethoprim-sulfamethoxazole. Int J Dermatol 2000; 39: 621-623
12. Zahar JR, Robin M, Azoulay E et al. Pneumocystis jiroveci pneumonia in critically ill patients with malignancy: a descriptive study. Clin Infect Dis 2002; 35: 929-934